News
Sensorion Discloses No Exposure To Silicon Valley Bank Closure
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, has learned that Silicon Valley Bank (SVB) has
Valbiotis Announces the Last Visit of the Last Patient in the Phase II/III REVERSE-IT Study on TOTUM•63, in Partnership with Nestlé Health Science
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, committed to scientific innovation for preventing
Charles River Launches Apollo™, an Industry-Leading, Secure, Cloud-Based Platform for Real-Time Toxicology Study Data
Charles River Laboratories International, Inc. (NYSE: CRL) today launched Apollo™, an industry-leading, secure, cloud-based platform for drug developers that provides access to study data, study
Premier, Inc. Named One of the 2023 World’s Most Ethical Companies® by Ethisphere® for 16th Consecutive Year
Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement and technology company, has been recognized by Ethisphere®, a global leader in defining and advancing the standards of ethical
QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended
Charles River Laboratories to Present at Barclays Global Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays Global Healthcare Conference on Wednesday, March 15th, at 10:15 a.m. ET. Management
Pfizer Invests $43 Billion to Battle Cancer
Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology
DexCom Comments on SVB Relationship
DexCom, Inc. (NASDAQ: DXCM), today issued the following statement in response to speculation following the developments at Silicon Valley Bank, including a recent CNBC article:
“Dexcom does not
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-News: Abivax does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution
Agilent Announces End-to-End Digital Pathology Workflow Solution at USCAP 2023
Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated end-to-end solution for digital pathology that brings together best-in-class products from Agilent, Visiopharm, Proscia®
Agilent Announces End-to-End Digital Pathology Workflow Solution at USCAP 2023
Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated end-to-end solution for digital pathology that brings together best-in-class products from Agilent, Visiopharm, Proscia®
Agilent Announces Digital Pathology Scanner Distribution Agreement with Hamamatsu
Agilent Technologies Inc. (NYSE: A) today announced it has partnered with Hamamatsu Photonics K.K., a leading provider of whole slide imaging systems, to incorporate their NanoZoomer range
Agilent Announces Digital Pathology Scanner Distribution Agreement with Hamamatsu
Agilent Technologies Inc. (NYSE: A) today announced it has partnered with Hamamatsu Photonics K.K., a leading provider of whole slide imaging systems, to incorporate their NanoZoomer range
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics, Inc.
LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology
LEO Pharma, a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is
Agilent Again Named One of Barron’s 100 Most Sustainable Companies
For the sixth consecutive year, Agilent Technologies (NYSE: A) is ranked among the top 20 in Barron’s list of America’s 100 Most Sustainable Companies.
The ranking is based on the performance of
Agilent Announces Acquisition of e-MSion, Early-Stage Company Behind ECD Technology that Helps Accelerate Drug Development
Agilent Technologies Inc. (NYSE: A) today announced the acquisition of e-MSion, an early-stage company behind the innovative electron capture dissociation (ECD) technology known as the ExD cell.
Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces the appointment of Dr.
LivaNova to Present at the Barclays Global Healthcare Conference
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present in a fireside chat at the Barclays
Humana’s Economic Impact in Florida Totals $48 Billion
An independent economic research analysis estimated that leading health and well-being company Humana Inc. (NYSE: HUM) would contribute a total of $48 billion in overall economic impact in the